PK Driven Prophylaxis for Hemophilia A

Interest of Preventive Personalized Treatment in Hemophilia A

The purpose of this study is to evaluate the implementation of pharmacokinetic (PK) driven prophylaxis in current clinical practice

Starting from 3 pharmacokinetic (PK) points, data are entered in the PK calculator device, and treatment dose is adjusted following the results of PK values obtained and clinical bleeding data

Inclusion Criteria:

• Male Patient
• Severe or moderately severe haemophilia A (FVIII = 2 %), preventively treated (processing) by ADVATE for at least 6 months,
• At last 6 years old,
• An informed consent must be signed by the patient or his legal representative for the patients minor.
• Affiliated to a national insurance scheme

Exclusion Criteria:

• Previous or actual treatment with FVIII inhibitors > 0,6 UB at the selection
• Induction of immune tolerance
• Planned orthopedic surgery for the 18 next months
• Any other haemostatic pathology
• Any treatment interacting on the haemostasis
• Patient under guardianship
• Patient participating in another biomedical research